贾 兵   副研究员、博士生导师

联系方式

Email：jiabing@bjmu.edu.cn

电话：010-82802871

办公室：中心实验楼220

个人简介

2001年参与组建北京大学医学同位素研究中心以来，长期从事放射性核素分子显像药物与肿瘤放射靶向治疗研究。作为项目负责人先后主持国家自然科学基金5项及北京市自然科学基金1项；作为子课题负责人承担并参与科技部“973”计划、“重大新药创制”专项、国家自然科学基金“国家重点科研仪器研制项目”等各1项。获授权国家发明专利18项（其中2项已完成市场化转让，并分别推进1类新药申报）。在国内外学术期刊发表论文100余篇，其中SCI论文89篇。2023年获教育部技术发明特等奖。

研究方向

放射性药物

肿瘤分子影像

肿瘤放射靶向治疗

主要学术任职

中国核学会同位素分会理事

中国核学会放射性药物分会常务理事

近五年代表性论文

1. A Novel PSMA/FAP-Specific Radiotracer ^99mTc-HFaPSMA for Diagnosis of Wang Y, Li X, Li C, Xing H, Gao R, Jia B*. PSMA-Negative Prostate Cancer: From Preclinical Validation to Clinical Translation.  J Med Chem . 2025, 28;68(16):17598-17610

2. Li C, Li X, Wang Y, Bai Z, Wang Y, Gao R, Jia B*. Technetium-99m-Labeled Fibroblast Activation Protein-Targeted Nanobody Radiotracer: from Preclinical Development to Clinical Translation in Cancer Imaging.  ACS Pharmacol Transl Sci . 2025, 8(8):2673-2682.

3. Zhou X^#, Yan S^#, Ma X, Zhu H, Liu B, Yang X, Jia B*, Yang Z*, Wu N*, Li N*. Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancer.  Eur J Nucl Med Mol Imaging . 2025, 52(7): 2343-2354.

4. Ma X^#, Hu B^#, Zhou X, Wang L, Chen H, Xie F, Zhu H*, Jia B*, Yang Z*. Development and First-in-Human evaluation of a Site-Specific [¹⁸F]-Labeled PD-L1 nanobody PET radiotracer for noninvasive imaging in NSCLC.  Bioorg Chem . 2025,156:108222

5. Bai Z^#, Xie X^#, Li C, Wang Y, Wang Y, Li H, Gao R*, Jia B*. Claudin18.2-Targeted SPECT/CT Imaging for Gastric Cancer: Preclinical Evaluation and Clinical Translation of the ^99mTc-Labeled Nanobody (PHG102) Radiotracer.  Acs Pharmacol Transl . 2024, 7(8):2465-2475

6. Wang R^#, Bai Z^#, Zhong W^#, Li C, Wang J, Xiang J, Du J*, Jia B*, Zhu Z*. Synthesis, preclinical evaluation and pilot clinical translation of [⁶⁸Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer.  Eur J Nucl Med Mol Imaging . 2024, 51(12):3731-3743

7. Hu B, Ma X, Shi L, Liu T, Li L, Yao M, Li C, Jia B*. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel ^99mTc-Labeled Nanobody Tracer with Rapid Renal Clearance.  Mol Pharm . 2024, 21(4):1977-1986.

8. Ma M^#, Yang G^#, Zhao M, Liu Y, Ge X, Jia B*, Gao S*. Synthesis and Preliminary Study of ^99mTc-Labeled HYNIC-FAPi for Imaging of Fibroblast Activation Proteins in Tumors.  Mol Pharm . 2024, 21(2):735-744

9. Xie B^#, Li L^#, Lin M^#, Nanna M, Su Y, Hua C, Leng C, Gan Q, Xi XY, Wang Y, Yao D, Wang L, Yu L, Zhao L, Zhang YP, Dou K, Su P, Lv X*, Jia B*, Yang MF*. ^99mTc-HFAPi imaging identifies early myocardial fibrosis in the hypertensive heart.  J Hypertens . 2023, 41(10):1645-1652

10. Ma X^#, Zhou X^#, Hu B^#, Li X, Yao M, Li L, Qin X, Li D, Yao Y, Hou X, Liu S, Chen Y, Wang Z, Zhou W, Li N*, Zhu H*, Jia B*, Yang Z*. Preclinical evaluation and pilot clinical study of [⁶⁸Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging.  Eur J Nucl Med Mol Imaging . 2023, 50(13):3838-3850

11. Jia X^#, Li X^#, Jia B^#, Yang Y, Wang Y, Liu Y, Ji T, Xie X, Yao Y, Qiu G, Deng H, Zhu Z, Chen S, Yang A, Gao R*. The role of [^99mTc]Tc-HFAPi SPECT/CT in patients with malignancies of digestive system: first clinical experience.  Eur J Nucl Med Mol Imaging . 2023, 50(4):1228-1239

12. Qin X, Guo X, Liu T, Li L, Zhou N, Ma X, Meng X, Liu J, Zhu H*, Jia B*, Yang Z*. High in-vivo stability in preclinical and first-in-human experiments with [¹⁸F]AlF-RESCA-MIRC213: a ¹⁸F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers.  Eur J Nucl Med Mol Imaging . 2023, 50(2):302-313

13. Li L, Liu T, Shi L, Zhang X, Guo X, Hu B, Yao M, Zhu H, Yang Z, Jia B*, Wang F. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.  Theranostics . 2022, 12(12):5551-5563.

14. Shi L, Chen B, Liu T, Li L, Hu B, Li C, Jia B*, Wang F*. ^99mTc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression.  Mol Pharm . 2022, 19(7):2583-2594

15. Hu B, Liu T, Li L, Shi L, Yao M, Li C, Ma X, Zhu H, Jia B*, Wang F. IgG-Binding Nanobody Capable of Prolonging Nanobody-Based Radiotracer Plasma Half-Life and Enhancing the Efficacy of Tumor-Targeted Radionuclide Therapy.  Bioconjug Chem . 2022, 33(7):1328-1339.

16. Liu T, Wu Y, Shi L, Li L, Hu B, Wang Y, Gao H, Yu X, Zhang X, Zhao H, Wan Y, Jia B*, Wang F*. Preclinical evaluation of [^99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT.  Eur J Nucl Med Mol Imaging . 2022, 49(6):1810-1821

17. Zhang X, Chen M, Zhang Y, Hou Y, Wu Y, Yao M, Li L, Shi L, Liu T, Hu B, Zhao H, Li X, Shi J, Jia B*, and Wang F. Monoclonal-Antibody-Templated Gold Nanoclusters for HER2 Receptors Targeted Fluorescence Imaging.  ACS Appl Bio Mater . 2020, 3, 10, 7061–7066.

18. Gao S^#, Jia B^#, Feng G^#, Dong C^#, Du H, Bai L, Zhong Q, Ma Q, Zeng M, Wang F*. First-in-human Pilot Study of an Integrin α6-targeted Radiotracer for SPECT Imaging of Breast Cancer.  Signal Transduct Target Ther . 2020, 5(1):147